Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer)

摘要: The last decade has witnessed tremendous advances in the treatment of patients with cancer. Chief among these is discovery and successful development new, targeted cancer therapies. These therapies are highly effective genetically defined subsets patients, i.e., whose tumors harbor specific genetic abnormalities. In contrast to previous chapters focusing on germline alterations that increase risk cancer, this chapter will examine cancers somatic confer sensitivity molecularly Examples include imatinib for chronic myelogenous leukemia gastrointestinal stromal tumors, traztuzumab lapatinib HER2-amplified breast erlotinib, a tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR), EGFR-mutant nonsmall cell lung (see Table 15.1).